The Pulsmed Hospital together with the Medical University of Lodz, Clinical and Didactic Center (one of the most modern facilities in Europe) begins modern treatment of type 2 diabetes and chronic diseases that are complications of diabetes: angiopathy, retinopathy, cardiomyopathy or diabetic nephropathy.
Finding an effective treatment method is one of the biggest challenges of modern medicine. Recent oral medications used at the initial stage of treatment to optimize blood glucose levels are only symptomatic.
The project anticipates the use of mesenchymal stem cells (MSCs) from patients’ own adipose tissue (ADSC – Adipose Derived Stem Cells) for the treatment of diabetes mellitus type II (T2DM) and its complications. The aim of the project is to develop innovative therapy and evaluate its effectiveness in the treatment of T2DM and organ complications: angiopathy and diabetic retinopathy, cardiomyopathy, nephropathy, diabetic polyneuropathy.
Previous treatment proceedings in diabetes was based on symptomatic treatment and consisted of the use of oral drugs or exogenous insulins (controlled injection form to compensate the level of sugar in the blood). In recent years, MSCs obtained from various tissues are the subject of research and are also used in the treatment of diabetes. This is due to the ability of MSCs to unlimited renewal, immunomodulatory properties, ability to migrate to damage sites, and differentiation into specific cells and tissue. MSCs from adipose tissue can be used in diabetes treatment, taking into account the fact that these stem cells have the ability to: differentiation into pancreatic beta cells that produce insulin; regeneration of existing Langerhans cells of the pancreas by secretion of cytokines and growth factors (VEGF, IGF-1, PDGF-BB, angiopoietin-1, etc.); protection of endogenous islet cells through immunoregulatory and antioxidant activity and inhibition of T cell proliferation; improvement of organ and tissue insulin sensitivity through secretion and activation of various factors; reduction of proinflammatory cytokines and chemokines; stimulation of M1 macrophages transfer into anti-inflammatory M2.
MSCs activity in diabetes helps to stabilize blood glucose levels and is effective in the treatment of chronic complications of organ diabetes listed above. Most research uses stem cells derived from bone marrow, umbilical cord blood, or mature cells of various tissues that have been restored to stem cells.
How to start treatment?
If you want to use therapy using your own stem cells from adipose tissue, contact us by phone: +48 668 696 911 and you will receive comprehensive information about the treatment.